Phan V H Giang, Nguyen Bich-Phuong Thi, Nguyen Nhi Yen, Tran Cam-Nhung Dinh, Nguyen Quynh-Nhu Doan, Luu Cuong Hung, Manivasagan Panchanathan, Jang Eue-Soon, Yang Deok Chun, Yang Dong Uk, Li Yi, Conde João, Thambi Thavasyappan
Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
Int J Biol Macromol. 2025 May;308(Pt 1):142254. doi: 10.1016/j.ijbiomac.2025.142254. Epub 2025 Mar 20.
Osteoporosis, a common disorder, is characterized by a systemic reduction in bone mass and structural integrity, resulting in brittle bones. Reducing bone loss and enhancing bone density through oral administration of biopharmaceuticals provides significant advantages, including convenience and non-invasiveness for patients. However, challenges such as poor absorption and enzymatic degradation necessitate the development of innovative drug delivery systems. This research introduces a core-shell hydrogel system inspired by the natural architecture of Longan fruit, constructed from pectin and chitosan biopolymers, designed to create biocapsules and sustain the release of biodrugs. In this system, salmon calcitonin (sCT) was encapsulated within mesoporous silica nanoparticles (MSNs) and incorporated into the core of the beads. The synthesis of the core-shell hydrogel beads was carefully regulated by adjusting the immersion time and concentration of the crosslinker. The hydrogel beads demonstrated durability, with the pectin shell effectively preventing rapid degradation in the stomach, while the chitosan layer enhanced adhesion to the intestinal walls, safeguarded sCT, and enabled sustained drug release over an extended period of up to 30 h. Furthermore, biocompatibility tests indicated minimal cytotoxicity and hemolysis. Cellular uptake assays demonstrated that the core-shell beads effectively encapsulated sCT and ensured its prolonged release to CT-26 cells. This study presents a promising platform for oral sCT delivery, offering enhanced efficacy, patient compliance, and a potential replacement for injection-based therapies.
骨质疏松症是一种常见疾病,其特征是骨量和结构完整性系统性降低,导致骨骼脆弱。通过口服生物药物减少骨质流失并提高骨密度具有显著优势,包括对患者而言方便且无创。然而,诸如吸收不良和酶降解等挑战使得有必要开发创新的药物递送系统。本研究引入了一种受龙眼果实天然结构启发的核壳水凝胶系统,该系统由果胶和壳聚糖生物聚合物构建而成,旨在制造生物胶囊并实现生物药物的持续释放。在该系统中,鲑鱼降钙素(sCT)被包裹在介孔二氧化硅纳米颗粒(MSNs)中,并掺入微珠的核心。通过调整交联剂的浸泡时间和浓度,仔细调控核壳水凝胶微珠的合成。水凝胶微珠表现出耐久性,果胶壳有效防止在胃中快速降解,而壳聚糖层增强了对肠壁的粘附性,保护了sCT,并能在长达30小时的延长时间内实现药物持续释放。此外,生物相容性测试表明细胞毒性和溶血作用极小。细胞摄取试验表明,核壳微珠有效地包裹了sCT,并确保其向CT - 26细胞的长期释放。本研究为口服sCT递送提供了一个有前景的平台,具有增强的疗效、患者依从性,并有可能替代基于注射的疗法。